MK-0429

• Description :

  MK-0429 (L-000845704) is an orally active, potent, selective and nonpeptide pan-integrin antagonist with IC50 values of 1.6 nM, 2.8 nM, 0.1 nM, 0.7 nM, 0.5 nM and 12.2 nM for αvβ1, αvβ3, αvβ5, αvβ6, αvβ8 and α5β1, respectively[1][2][3].

• Product Name Alternative :

  L-000845704

• UNSPSC :

  12352005

• Hazard Statement :

  H360, H373

• Target :

  Integrin

• Type :

  Reference compound

• Related Pathways :

  Cytoskeleton

• Applications :

  COVID-19-immunoregulation

• Field of Research :

  Inflammation/Immunology; Cancer

• Assay Protocol :

  https://www.medchemexpress.com/MK-0429.html

• Purity :

  99.50

• Solubility :

  DMSO : 100 mg/mL (ultrasonic) |H2O : 2.78 mg/mL (ultrasonic)

• Smiles :

  O=C1N([C@H](C2=CC=C(OC)N=C2)CC(O)=O)CCN1CCCC3=NC4=C(C=C3)CCCN4

• Molecular Formula :

  C23H29N5O4

• Molecular Weight :

  439.51

• Precautions :

  H360, H373

• References & Citations :

  [1]Hutchinson JH, et al. Nonpeptide alphavbeta3 antagonists. 8. In vitro and in vivo evaluation of a potent alphavbeta3 antagonist for the prevention and treatment of osteoporosis. J Med Chem. 2003 Oct 23;46 (22) :4790-8.|[2]Pickarski M, et al. Orally active αvβ3 integrin inhibitor MK-0429 reduces melanoma metastasis. Oncol Rep. 2015 Jun;33 (6) :2737-45.|[3]Xiaoyan Zhou, et al. An integrin antagonist (MK-0429) decreases proteinuria and renal fibrosis in the ZSF1 rat diabetic nephropathy model. Pharmacol Res Perspect. 2017 Oct;5 (5) :e00354.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  -20°C, 3 years; 4°C, 2 years (Powder)

• Scientific Category :

  Reference compound1

• Clinical Information :

  Phase 2

• Isoform :

  α5β1; αvβ1; αvβ3; αvβ5; αvβ6; αvβ8

• CAS Number :

  [227963-15-7]